



## INSIDE THIS ISSUE

- Protocol update – UCNTEMOZ, UGIFUIP, GUEP, GUVIP2, LUVIN, LYACOP6, LYACOP12, LYPALL
- Patient handouts – capecitabine (Xeloda®)
- Drug Update – BCG addendum, Temozolomide

FAX request form and IN TOUCH phone list are provided if additional information is needed.

## PROTOCOL UPDATE

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **UCNTEMOZ** – new: Temozolomide as second line chemotherapy for recurrent malignant gliomas
- **UGIFUIP** – revised (added precautions, dose modifications for renal and hepatic dysfunction): Chemotherapy of pseudomyxoma peritonei
- **GUBEP** – revised (treatment duration by risk category clarified, prophylactic antibiotics deleted, precautions added): Bleomycin, etoposide, cisplatin for nonseminoma germ cell cancers
- **GUEP** – revised (prophylactic antibiotics deleted, precautions added): Etoposide-cisplatin protocol for seminoma and nonseminoma germ cell cancer
- **GUVIP2** – revised (prophylactic antibiotics deleted, precautions added): Nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, MESNA
- **LUVIN** – revised (reference added): Treatment for advanced non-small cell lung cancer with vinorelbine in elderly patients

- **LYACOP6** – reformatted: Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone for 6 weeks
- **LYACOP12** – revised (follicular large cell lymphoma deleted from eligibility, monitoring details added to dose modifications for hepatotoxicity): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone
- **LYPALL** – revised (cladribine, fludarabine, mitoxantrone deleted; dexamethasone added; etoposide dose range changed): Lymphoma palliative chemotherapy

## PATIENT HANDOUTS

**Capecitabine** – revised for the fluid with which the patient can take the medication. A request to the manufacturer, Hoffmann-La Roche, has indicated that capecitabine can be taken with water or juice.

## DRUG UPDATE

**Temozolomide** – this is a new oral alkylating agent which is used as a second line treatment of adult patients with glioblastoma multiforme or anaplastic astrocytoma. Temozolomide is an analogue of dacarbazine (DTIC) and both agents are converted into the same active metabolite in the body. The most common adverse effects are myelosuppression and mild to moderate nausea and vomiting. Temozolomide is currently not covered by the Class II drug benefit list and requires “Undesignated Indication” approval prior to use (see protocol UCNTEMOZ above).

**BCG interchangeability** – (addendum to Sep/Oct Update) Please note that each vial of OncoTICE® (Organon Teknika) contains BCG vaccine TICE strain 50 mg, which is equivalent to 1 to 8 x 10<sup>8</sup> colony forming units (CFU). Currently the product monograph only states that it contains 1 to 8 x 10<sup>8</sup> CFU.

---

**Editorial Review Board**

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD

Sandi Broughton, BA(Econ), MSc

Jack Chritchley, MD

Linda Yearwood, MSN

Lynne Nakashima, PharmD

Kelly Uyeno, CGA

Gigi Concon (Secretary )

<b>IN TOUCH</b>	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322
Communities Oncology Network	(604) 877-6098 Ext 2744	Toll-Free 1-(800)-663-3333 Ext 2744
Nursing Professional Practice	(604)-877-6098 Ext 2623	Toll-Free 1-(800)-663-3333 Ext 2623
Pharmacy Professional Practice	(604)-877-6098 Ext 2247	Toll-Free 1-(800)-663-3333 Ext 2247
Provincial Systemic Program	(604)-877-6098 Ext 2247	Toll-Free 1-(800)-663-3333 Ext 2247
Francis Hu, CON Pharmacist	(604)-877-6098 Ext 2515	<a href="mailto:francish@bccancer.bc.ca">francish@bccancer.bc.ca</a>
Mário de Lemos, Update Editor	(604)-877-6098 Ext 2288	<a href="mailto:mdelemos@bccancer.bc.ca">mdelemos@bccancer.bc.ca</a>

## RADIATION CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Patient Handouts:	H:\everyone\systemic\chemo\Pt_Educ
	H:\everyone\systemic\chemo\Pt_Educ\Capecitabine_Handout.doc
Protocol Summaries	H:\everyone\systemic\chemo\Protocol
	H:\everyone\systemic\chemo\Protocol\CNS\ucntemoz.doc
	H:\everyone\systemic\chemo\Protocol\GI\ugifuip.doc
	H:\everyone\systemic\chemo\Protocol\GU\gubep.doc
	H:\everyone\systemic\chemo\Protocol\GU\guedp.doc
	H:\everyone\systemic\chemo\Protocol\GU\guvip2.doc
	H:\everyone\systemic\chemo\Protocol\Lung\luvin.doc
	H:\everyone\systemic\chemo\Protocol\Lymphoma\lyacop6.doc
	H:\everyone\systemic\chemo\Protocol\Lymphoma\lyacop12.doc
	H:\everyone\systemic\chemo\Protocol\Lymphoma\lypall.doc
Index of Protocol Summaries	H:\everyone\systemic\chemo\Protocol\Index\Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List	H:\everyone\systemic\chemo\Reimburs\Benefit.doc
Class 2 Form	H:\everyone\systemic\chemo\Reimburs\Class2.doc

## BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

**FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**

**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247**

**PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES**

*I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:*

E-mail (Word 6.0)

@

Fax

(      )

Attn:

### UPDATES Please Fax-Back information below:

<input type="checkbox"/>	All items
	Patient Handouts:
<input type="checkbox"/>	Capecitabine (Xeloda®)
	Protocol Summaries:
<input type="checkbox"/>	UCNTEMOZ
<input type="checkbox"/>	UGIFUIP
<input type="checkbox"/>	GUBEP
<input type="checkbox"/>	GUEP
<input type="checkbox"/>	GUVIP2
<input type="checkbox"/>	LUVIN
<input type="checkbox"/>	LYACOP6
<input type="checkbox"/>	LYACOP12
<input type="checkbox"/>	LYPALL
<input type="checkbox"/>	Index: Protocol Summaries (current month)
	Reimbursement
<input type="checkbox"/>	Benefit Drug List (01 Nov 99)
<input type="checkbox"/>	Class 2 Form (01 Nov 99)

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at [bulletin@bccancer.bc.ca](mailto:bulletin@bccancer.bc.ca)